Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Ivabradine

(Corlanor®)

Ivabradine

Drug updated on 3/28/2024

Dosage FormTablet (oral; 5 mg, 7.5 mg); Solution (oral; 5 mg/5 mL)
Drug ClassHyperpolarization-activated cyclic nucleotide-gated channel blockers
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
  • For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Ivabradine (Corlanor) is indicated for reducing the risk of hospitalization due to worsening heart failure in adult patients with stable, symptomatic chronic heart failure and reduced left ventricular ejection fraction.
  • The drug also treats stable symptomatic heart failure caused by dilated cardiomyopathy in pediatric patients aged 6 months and older.
  • A review of 23 systematic reviews/meta-analyses shows that ivabradine (Corlanor), when combined with background therapy, significantly reduces hospitalizations for heart failure or cardiovascular death.
  • Ivabradine (Corlanor) has been found to improve cardiac function by reducing the heart rate, improving left ventricular ejection fraction, and decreasing left ventricular dimensions.
  • In terms of safety profile, ivabradine's use on top of background therapy presents a comparable risk level to those treated solely with background therapy; however it does increase the incidence of atrial fibrillation especially in patients with LVEF >40% as well as visual disturbances and asymptomatic bradycardia among CHF patients compared to placebo or standard care groups.
  • Subgroup analysis suggests consistent benefits across various patient subgroups but data on specific populations such as those suffering from HFpEF or advanced NYHA class IV symptoms are limited or inconclusive at this time.
  • Compared against other drugs like beta-blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin-converting enzyme inhibitors (ACEIs), ARNIs and SGLT2 inhibitors used for treating HFrEF conditions - while effective - ivabradine may not always feature prominently within most beneficial combinations particularly regarding mortality reduction outcomes where combination therapies involving ARNI’s Beta-blockers MRA’s & SGLT2 inhibitors were found more effective overall.
  • Ivabradine improves health-related quality-of-life measures along with New York Heart Association (NYHA) class, indicating its effectiveness in managing symptoms of heart failure.

Product Monograph / Prescribing Information

Document TitleYearSource
Corlanor (ivabradine) Prescribing Information.2021Amgen Inc., Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Ivabradine in patients with heart failure: a systematic literature review2023Journal of market access & health policy
Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis2023Drugs in R&D
Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction2023The American journal of cardiology
The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: a systematic review and meta-analysis2023Frontiers in cardiovascular medicine
Ivabradine and atrial fibrillation: a meta-analysis of randomized controlled trials.2022Journal of Cardiovascular Pharmacology
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction2022JACC. Heart failure
Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction2022Journal of internal medicine
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis2022European heart journal. Cardiovascular pharmacotherapy
Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis2022Frontiers in cardiovascular medicine
Effectiveness and safety of ivabradine in the treatment of acute myocardial infarction: a systematic review and meta-analysis.2021Annals of Palliative Medicine
Pharmacotherapies in heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.2021Cureus
Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis.2021European Journal of Heart Failure
Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: meta-analysis of randomized controlled trials.2021Clinical Cardiology
Effect of ivabradine on exercise capacity in individuals with heart failure with preserved ejection fraction.2021Heart Failure Reviews
Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction2021Canadian journal of physiology and pharmacology
Effect of ivabradine on major adverse cardiovascular events and mortality in critically ill patients: a systematic review and meta-analyses of randomised controlled trials with trial sequential analyses.2020British Journal of Anaesthesia
New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis2020Medicine
Effects of Ivabradine on Cardiac Remodeling in Patients With Stable Symptomatic Heart Failure: A Systematic Review and Meta-analysis2020Clinical therapeutics
Effect of Ivabradine on Left Ventricular Diastolic Function, Exercise Tolerance and Quality of Life in Patients With Heart Failure: A Systemic Review and Meta-Analysis of Randomized Controlled Trials2020Cardiology research
Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure2019International heart journal
The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis.2018International Journal of Clinical Pharmacy
The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis2018International Journal of Clinical Pharmacy
Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis2018European journal of heart failure

Clinical Practice Guidelines

Document TitleYearSource
2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction.2021Journal of the American College of Cardiology
The Medical journal of Australia 2018The Medical journal of Australia